Pharmacokinetics of Voriconazole in Adult ECMO Patients
Key facts
- Who runs it
- University Hospitals, Leicester
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 32 people enrolled
- Started
- 10 Aug 2021
- Ended
- 31 May 2025
- Type of study
- Observational
- Treatments tested
- 5 blood samples
- Determination of CYP2C19 genotype
- Record updated
- 6 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adults aged ≥18 years
- Admitted to ICU on ECMO support
- Positive influenza or SARS-CoV-2 PCR from nasal, throat swab, BAL or other respiratory specimen
- Positive invasive aspergillosis infection (positive Aspergillus species culture from respiratory specimen or positive serum galactomannan) or strong clinical suspicion of invasive aspergillosis infection based on symptoms, CT, CXR
Who cannot take part
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
- No participants < 18 years of age
- Not requiring ECMO support
- No positive influenza or SARS-CoV-2 results
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Given the high burden of fungal co-infection in patients admitted to ICU and improved outcomes with prompt anti-fungal treatment, it is of vital importance that the doses of anti-fungal are optimum to improve the dismal outcome of influenza/Covid-19 Associated Pulmonary Aspergillosis.
Read full original descriptionShow less
Due to the reported difficulties in dosing appropriately in ECMO patients, a prospective observational study is required to accurately evaluate the pharmacokinetics of voriconazole in patients supported on ECMO. This is to ensure that the dose of voriconazole is optimised to improve efficacy and reduce toxicity.
The group in the trial
- Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support
Adult (\>18 years) patients with severe influenza / Covid-19 supported on ECMO and with confirmed or suspected aspergillosis infection.
Treatment: 5 blood samples and Determination of CYP2C19 genotype
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational Pharmacokinetic Study of Intravenous Voriconazole Used for Treatment of Invasive Aspergillosis in Adult Patients With Severe Influenza / COVID-19 Supported With Extra-corporeal Membrane Oxygenation (ECMO)
- Publications
- Time-varying voriconazole clearance during extracorporeal membrane oxygenation.Antimicrobial agents and chemotherapy, 2026
- Record updated
- 6 January 2026